In our continuing series with members of the Peggy Lillis Foundation, here is an opportunity to hear about people’s experiences, lessons learned, and the new treatments that can lead to hope and not the hopelessness people have been living with during their ordeals.
Misinformation created unnecessary hospitalizations and mortality and demonstrated the chasm in public health communication.
Alyssa Dykstra is experiencing a drastic increase in paying for her medication for autoimmune arthritis. Insurers are utilizing a loophole provided by the federal government to allow them to disallow coupons, thus raising prescription costs for patients.
With the FDA approval of nirsevimab-alip (Beyfortus), which is indicated for prevention of respiratory syncytial virus (RSV) in infants, clinicians will need to have important conversations with families around this monoclonal antibody, beginning this fall.
A clinician offers a glimpse of what it is like to treat infants with respiratory syncytial virus (RSV). And with the recent FDA approval of nirsevimab, how that will likely benefit families and the youngest population.
A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.
This conference is addressing antimicrobial resistance (AMR) from different perspectives and look at strategies to reduce this global health problem.
A company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b (HBV).
Lumen Bioscience's C diff therapy, LMN-201, combines four therapeutic proteins that act synergistically to neutralize both the C difficile bacterium and the toxin that causes its virulence directly in the patient’s gastrointestinal tract.
Although the literature and science may change, hanging onto beliefs about therapeutics is a tradition passed down from instructors to learners. A change in this paradigm may be warranted.
This variant, which is an ancestor of Omicron, is an emerging variant that is being seen most frequently in Utah, California, and New York State.
The Outpatient Automated Stewardship Information System (OASIS) is a platform that allows clinicians the ability to improve their prescribing practices in hopes of delivering a more judicious approach and moving towards stewardship.
HIV testing is for everyone, explains Dr. Uri Belkind, regardless of sexual orientation, race, or gender.
A company has developed an intelligence platform for better understanding influenza and other viral trends.
Pfizer's RSVpreF vaccine candidate has shown promising efficacy in preventing severe lower respiratory illness caused by RSV in infants. With the potential approval of RSVpreF, pediatric care could undergo a significant positive change.
RSVpreF receives strong support from the FDA's VRBPAC, with positive votes for efficacy and safety. The vaccine shows promise in preventing severe respiratory illness in infants, and an FDA authorization decision is expected in August 2023.
Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.
Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.
Steven Varga, PhD, explains why infants and young children are so susceptible to severe respiratory syncytial virus (RSV) infections.
Carlos Del Rio, MD, updates clinicians and the public on where we are now on the respiratory virus and the modalities to treat and prevent severe disease.
A clinician provides insights on this significant topic as well as resources in finding information on them.
Joseph Reilly, BS, PharmD, BCGP; Candace Cotto, RN; and Andrew Skinner, MD, review C. difficile infection (CDI), its risk factors, symptoms, and quality of life for the patient.
Experts provide an overview of the gut microbiome and its importance to nutrition and overall health.
RSV expert Steven Varga, PhD, describes the failed vaccine trials that paved the way for the world's first respiratory syncytial virus (RSV) vaccine, as well as the innovations still needed to protect vulnerable populations against RSV infection.
A clinician offers ideas about who to target for immunization and strategic considerations when having these conversations.
One of the most challenging aspects of clinicans’ jobs is giving patients and staff bad news. A clinician offers some strategies to help shape an approach in having these conversations.
Artificial intelligence (AI) is being utilized already says one clinician. She explains her optimism about the technology, and says it will help augment any potential challenges providers have now or in the future.
A paradigm shift is emerging when it comes to the clinical approach to prescribing antibiotics. One clinician weighs in on using this class of therapeutics more judiciously.
An epidemiologist offers some insights on what we need to take into a potential next pandemic including infrastructure investment and more effectively communicating messages to the public.
A key stakeholder offers his insights on the importance of the new Biden plan to eliminate hepatitis C as well as the federal strategy to get more people linkage to care for hepatitis B.
